Pharmacokinetics and Bioavailability of the Novel Rivastigmine Transdermal Patch Versus Rivastigmine Oral Solution in Healthy Elderly Subjects
- 1 February 2008
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 48 (2) , 246-252
- https://doi.org/10.1177/0091270007312154
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's diseaseActa Neurologica Scandinavica, 2009
- Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's diseaseInternational Journal of Geriatric Psychiatry, 2007
- A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patch versus capsuleInternational Journal of Geriatric Psychiatry, 2007
- Estimation of the Absolute Bioavailability of Rivastigmine in Patients with Mild to Moderate Dementia of the Alzheimer???s TypeClinical Pharmacokinetics, 2002
- Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase InhibitorsClinical Pharmacokinetics, 2002
- Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial Commentary: Another piece of the Alzheimer's jigsawBMJ, 1999
- RivastigmineDrugs & Aging, 1998
- Diagnosis and Treatment of Alzheimer Disease and Related DisordersJAMA, 1997
- Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's diseaseLife Sciences, 1996
- A new and rapid colorimetric determination of acetylcholinesterase activityBiochemical Pharmacology, 1961